In the face of important global challenges in infectious disease, the Bloomsbury Research Institute will combine the research excellence and international reach of the London School of Hygiene & Tropical Medicine and UCL to develop new drugs, vaccines and diagnostics.
The Institute will host world-leading scientists, conducting cutting-edge research on the major global killers – TB, HIV and malaria – as well as neglected tropical diseases and emerging microorganisms. Experts will also contribute to international efforts to address antibiotic resistance and develop new antimicrobials.
Catalyst funding will make a significant contribution towards the cost of constructing a new five-floor facility for the Institute with state-of-the-art laboratories in the heart of Bloomsbury, London.
Housing more than 200 scientists under the direction of leading microbiologist Professor Sharon Peacock, the Institute will be home to one of the highest concentrations of infectious disease researchers in Europe and will form a critical part of an expanding biosciences hub in London.
Partners include academic institutes, healthcare providers, industry and hospitals in the UK and overseas. The Institute’s work will impact public health policy in the UK and around the world, improving hospital and medical practice for patients.
Both the London School of Hygiene & Tropical Medicine and UCL are world-renowned for teaching, training and capacity building in low- and middle-income countries. They will build on this to identify new talent and train young researchers in innovative experimental and applied research. With a commitment to shaping the future of the next generation of scientists, the Institute will spark the imagination of young people through its outreach programmes.
|Total project funding||£51,000,000|